首页 > 最新文献

Open Forum Infectious Diseases最新文献

英文 中文
A Case of Syphilis With Ocular Involvement: Persistent Negative Serology in a Patient With Multiple Sclerosis. 一例眼部受累的梅毒患者:多发性硬化症患者血清持续阴性。
IF 3.8 4区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-29 eCollection Date: 2024-10-01 DOI: 10.1093/ofid/ofae563
Luca Pipitò, Irene Ganci, Andrea Cicero, Alice Annalisa Medaglia, Simona D'Avenia, Edoardo Mandalà, Cinzia Calà, Paola Di Carlo, Antonio Cascio

Diagnostic algorithms for syphilis are based on serology. However, with the advent of immunosuppressive therapies, these algorithms may fail. We report a case of an individual with multiple sclerosis on treatment with ofatumumab and secondary syphilis with visual and auditory systems involvement and persistent negative treponemal and nontreponemal tests.

梅毒的诊断算法以血清学为基础。然而,随着免疫抑制疗法的出现,这些算法可能会失效。我们报告了一例多发性硬化症患者的病例,患者在接受ofatumumab治疗后出现继发性梅毒,视觉和听觉系统受累,特雷波及非特雷波及梅毒试验持续阴性。
{"title":"A Case of Syphilis With Ocular Involvement: Persistent Negative Serology in a Patient With Multiple Sclerosis.","authors":"Luca Pipitò, Irene Ganci, Andrea Cicero, Alice Annalisa Medaglia, Simona D'Avenia, Edoardo Mandalà, Cinzia Calà, Paola Di Carlo, Antonio Cascio","doi":"10.1093/ofid/ofae563","DOIUrl":"https://doi.org/10.1093/ofid/ofae563","url":null,"abstract":"<p><p>Diagnostic algorithms for syphilis are based on serology. However, with the advent of immunosuppressive therapies, these algorithms may fail. We report a case of an individual with multiple sclerosis on treatment with ofatumumab and secondary syphilis with visual and auditory systems involvement and persistent negative treponemal and nontreponemal tests.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 10","pages":"ofae563"},"PeriodicalIF":3.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lyme Disease Prophylaxis by Single-Dose Doxycycline in the United States, 2010-2020. 2010-2020 年美国使用单剂量强力霉素预防莱姆病的情况。
IF 3.8 4区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-29 eCollection Date: 2024-10-01 DOI: 10.1093/ofid/ofae593
Grace E Marx, Alyssa Beck, Cate Corey, Candace C Fuller, Nicole Haug, Jenice S Ko, Dave Martin, Alison F Hinckley

Single-dose doxycycline after high-risk tick bites can prevent Lyme disease, which disproportionately affects children. We described single-dose doxycycline dispensings in an outpatient cohort in the United States. During 2010-2020, a total of 427 105 patients received ≥1 dispensing(s); most were aged ≥65 years. Lyme disease postexposure prophylaxis may be underprescribed for some groups, including children.

被高危蜱虫叮咬后服用单剂量强力霉素可预防莱姆病,而莱姆病对儿童的影响尤为严重。我们描述了美国门诊病人队列中的单剂量强力霉素配药情况。2010-2020 年间,共有 427 105 名患者接受了≥1 次配药;大多数患者的年龄≥65 岁。莱姆病暴露后预防可能对包括儿童在内的某些群体处方不足。
{"title":"Lyme Disease Prophylaxis by Single-Dose Doxycycline in the United States, 2010-2020.","authors":"Grace E Marx, Alyssa Beck, Cate Corey, Candace C Fuller, Nicole Haug, Jenice S Ko, Dave Martin, Alison F Hinckley","doi":"10.1093/ofid/ofae593","DOIUrl":"https://doi.org/10.1093/ofid/ofae593","url":null,"abstract":"<p><p>Single-dose doxycycline after high-risk tick bites can prevent Lyme disease, which disproportionately affects children. We described single-dose doxycycline dispensings in an outpatient cohort in the United States. During 2010-2020, a total of 427 105 patients received ≥1 dispensing(s); most were aged ≥65 years. Lyme disease postexposure prophylaxis may be underprescribed for some groups, including children.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 10","pages":"ofae593"},"PeriodicalIF":3.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of Laboratory-Confirmed Creutzfeldt-Jakob Disease From 3 Ontario Tertiary Care Centers Between 2012 and 2022: A Retrospective Cohort Study. 2012年至2022年安大略省3家三级医疗中心实验室确诊的克雅氏病特征:一项回顾性队列研究。
IF 3.8 4区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-28 eCollection Date: 2024-10-01 DOI: 10.1093/ofid/ofae551
Kayla Gaete, Soma Dalai, Ana Cabrera, Xena Li, Prameet M Sheth, Robert A Kozak, Mia J Biondi

Background: Globally, Creutzfeldt-Jakob disease (CJD) affects one in one million people annually, but there is a paucity of recent Canadian data. This study summarizes epidemiology trends and diagnostic timelines of laboratory-confirmed CJD cases in three tertiary Ontario hospitals.

Method: Using laboratory information systems, we identified 30 patients with a laboratory-confirmed CJD diagnosis between 2012 and 2022 at three major tertiary hospitals in Ontario. Retrospective chart reviews were then completed.

Results: Patients had a mean of 2.2 hospital visits (SD, 1.2) prior to being admitted for testing. The most common symptom presentations included loss of coordination (63.3%), behavioral changes (60%), progressive mobility loss (53.4%), memory loss (50.0%), and involuntary movements (50.0%). Magnetic resonance imaging findings showed potential CJD in 76.7% of cases, and 56.7% exhibited periodic sharp wave complexes characteristic of CJD on electroencephalogram. The mean duration from symptom onset to microbiologic testing was 91 days (SD, 90.7). End-point quaking-induced conversion (EP-QuIC) testing of cerebrospinal fluid was positive in 90.0% of patients, while 83.3% tested positive for 14-3-3 on enzyme-linked immunosorbent assay. Elevated cerebrospinal fluid 14-3-3 levels significantly correlated with shorter duration from symptom onset to death (R 2 = 0.71, F = 19.55, P = .0022). Post-diagnosis, 46.7% of patients were discharged home, 16.6% were transferred to external palliative care or hospice facilities, and 36.7% died during admission. The mean time from symptom onset to death was 121 days (SD, 120.7), and from diagnosis to death 35 days (SD, 83.9).

Conclusions: This study highlights the importance of early CJD consideration and laboratory testing when appropriate neurologic symptoms are present.

背景:在全球范围内,克雅氏病(CJD)的发病率为每年百万分之一,但加拿大的最新数据却很少。本研究总结了安大略省三家三级医院经实验室确诊的 CJD 病例的流行趋势和诊断时间表:利用实验室信息系统,我们确定了 2012 年至 2022 年期间在安大略省三家主要三级医院中经实验室确诊为 CJD 的 30 名患者。然后完成了回顾性病历审查:患者在入院接受检测前平均到医院就诊 2.2 次(SD,1.2)。最常见的症状表现包括协调能力丧失(63.3%)、行为改变(60%)、进行性活动能力丧失(53.4%)、记忆力丧失(50.0%)和不自主运动(50.0%)。磁共振成像结果显示,76.7%的病例可能患有 CJD,56.7%的病例在脑电图上表现出 CJD 特征性的周期性锐波复合体。从症状出现到微生物检测的平均持续时间为 91 天(SD,90.7)。90.0%的患者脑脊液终点震颤诱导转换(EP-QuIC)检测呈阳性,83.3%的患者酶联免疫吸附试验检测出14-3-3呈阳性。脑脊液 14-3-3 水平升高与患者从症状出现到死亡的时间缩短有明显相关性(R 2 = 0.71,F = 19.55,P = .0022)。确诊后,46.7%的患者出院回家,16.6%转入外部姑息治疗或临终关怀机构,36.7%在入院期间死亡。从症状出现到死亡的平均时间为121天(SD,120.7),从诊断到死亡的平均时间为35天(SD,83.9):本研究强调了在出现相应神经症状时及早考虑 CJD 并进行实验室检测的重要性。
{"title":"Characterization of Laboratory-Confirmed Creutzfeldt-Jakob Disease From 3 Ontario Tertiary Care Centers Between 2012 and 2022: A Retrospective Cohort Study.","authors":"Kayla Gaete, Soma Dalai, Ana Cabrera, Xena Li, Prameet M Sheth, Robert A Kozak, Mia J Biondi","doi":"10.1093/ofid/ofae551","DOIUrl":"10.1093/ofid/ofae551","url":null,"abstract":"<p><strong>Background: </strong>Globally, Creutzfeldt-Jakob disease (CJD) affects one in one million people annually, but there is a paucity of recent Canadian data. This study summarizes epidemiology trends and diagnostic timelines of laboratory-confirmed CJD cases in three tertiary Ontario hospitals.</p><p><strong>Method: </strong>Using laboratory information systems, we identified 30 patients with a laboratory-confirmed CJD diagnosis between 2012 and 2022 at three major tertiary hospitals in Ontario. Retrospective chart reviews were then completed.</p><p><strong>Results: </strong>Patients had a mean of 2.2 hospital visits (SD, 1.2) prior to being admitted for testing. The most common symptom presentations included loss of coordination (63.3%), behavioral changes (60%), progressive mobility loss (53.4%), memory loss (50.0%), and involuntary movements (50.0%). Magnetic resonance imaging findings showed potential CJD in 76.7% of cases, and 56.7% exhibited periodic sharp wave complexes characteristic of CJD on electroencephalogram. The mean duration from symptom onset to microbiologic testing was 91 days (SD, 90.7). End-point quaking-induced conversion (EP-QuIC) testing of cerebrospinal fluid was positive in 90.0% of patients, while 83.3% tested positive for 14-3-3 on enzyme-linked immunosorbent assay. Elevated cerebrospinal fluid 14-3-3 levels significantly correlated with shorter duration from symptom onset to death (<i>R</i> <sup>2</sup> = 0.71, <i>F</i> = 19.55, <i>P</i> = .0022). Post-diagnosis, 46.7% of patients were discharged home, 16.6% were transferred to external palliative care or hospice facilities, and 36.7% died during admission. The mean time from symptom onset to death was 121 days (SD, 120.7), and from diagnosis to death 35 days (SD, 83.9).</p><p><strong>Conclusions: </strong>This study highlights the importance of early CJD consideration and laboratory testing when appropriate neurologic symptoms are present.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 10","pages":"ofae551"},"PeriodicalIF":3.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Neonatal and Maternal Nasal Microbiome Among Neonates in the Intensive Care Unit. 重症监护室新生儿与母亲鼻腔微生物组的关系
IF 3.8 4区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-28 eCollection Date: 2024-11-01 DOI: 10.1093/ofid/ofae644
Shaoming Xiao, Wei Zhou, Ryan Caldwell, Slade Decker, Julia Oh, Aaron M Milstone

The neonatal nasal microbiota may help protect neonates in the neonatal intensive care unit from pathogen colonization and infection. This preliminary study characterized the biodiversity of nasal microbiota comparing neonates in the neonatal intensive care unit and their mothers, highlighting the potential of strain sharing between mother-neonate pairs.

新生儿鼻腔微生物群可能有助于保护新生儿重症监护室中的新生儿免受病原体定植和感染。这项初步研究对新生儿重症监护室中的新生儿及其母亲的鼻腔微生物群的生物多样性进行了比较,强调了母亲与新生儿之间菌株共享的可能性。
{"title":"Association of Neonatal and Maternal Nasal Microbiome Among Neonates in the Intensive Care Unit.","authors":"Shaoming Xiao, Wei Zhou, Ryan Caldwell, Slade Decker, Julia Oh, Aaron M Milstone","doi":"10.1093/ofid/ofae644","DOIUrl":"10.1093/ofid/ofae644","url":null,"abstract":"<p><p>The neonatal nasal microbiota may help protect neonates in the neonatal intensive care unit from pathogen colonization and infection. This preliminary study characterized the biodiversity of nasal microbiota comparing neonates in the neonatal intensive care unit and their mothers, highlighting the potential of strain sharing between mother-neonate pairs.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae644"},"PeriodicalIF":3.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Mycobacterium tuberculosis Sensitization and Insulin Resistance Among US Adults Screened for Type 2 Diabetes Mellitus. 在接受 2 型糖尿病筛查的美国成年人中,结核分枝杆菌致敏与胰岛素抵抗之间的关系。
IF 3.8 4区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-28 eCollection Date: 2024-10-01 DOI: 10.1093/ofid/ofae568
Itai M Magodoro, Aloice Aluoch, Brian Claggett, Moffat J Nyirenda, Mark J Siedner, Katalina A Wilkinson, Robert J Wilkinson, Ntobeko A B Ntusi

Background: Type 2 diabetes mellitus (T2DM) may be a long-term sequela of infection with Mycobacterium tuberculosis (Mtb) by mechanisms that remain to be fully explained. We evaluated the association between Mtb sensitization and T2DM and, via mediation analysis, the extent to which it is mediated by insulin resistance and/or β-cell failure.

Methods: Adults were assessed for T2DM by fasting plasma glucose, 2-hour oral glucose tolerance testing, and hemoglobin A1c; β-cell dysfunction and insulin resistance by homoeostasis model assessment 2; and Mtb sensitization by tuberculin skin testing. Associations between Mtb sensitization and T2DM were modeled with probit regression and decomposed into indirect effects of β-cell dysfunction and insulin resistance. Analyses were adjusted for sociodemographic, behavioral, and clinical characteristics.

Results: We included 1843 adults. Individuals with Mtb sensitization were older than those without Mtb (median [IQR], 54 [39-64] vs 47 [33-62] years). As compared with being uninfected, Mtb sensitization was associated with T2DM (adjusted absolute risk difference, 9.34% [95% CI, 2.38%-15.0%]; P < .001) and increased insulin resistance (adjusted median difference, 0.16 [95% CI, .03-.29]; P = .014) but not β-cell dysfunction (adjusted median difference, -3.1 [95% CI, -10.4 to 4.3]; P = .42). In mediation analyses, insulin resistance mediated 18.3% (95% CI, 3.29%-36.0%; P = .020) of the total effect of the association between Mtb sensitization and T2DM.

Conclusions: Definitive prospective studies examining incident T2DM following tuberculosis are warranted. Notwithstanding, our findings suggest that exposure to Mtb may be a novel risk factor for T2DM, likely driven by an increase in insulin resistance.

背景:2型糖尿病(T2DM)可能是结核分枝杆菌(Mtb)感染的长期后遗症,其机制尚待全面解释。我们评估了Mtb致敏与T2DM之间的关联,并通过中介分析评估了胰岛素抵抗和/或β细胞衰竭在多大程度上介导了这种关联:通过空腹血浆葡萄糖、2 小时口服葡萄糖耐量试验和血红蛋白 A1c 对成人进行 T2DM 评估;通过同源平衡模型评估 2 对 β 细胞功能障碍和胰岛素抵抗进行评估;通过结核菌素皮肤试验对 Mtb 敏化进行评估。Mtb致敏与T2DM之间的关系用probit回归建模,并分解为β细胞功能障碍和胰岛素抵抗的间接效应。分析对社会人口学、行为学和临床特征进行了调整:我们纳入了 1843 名成年人。Mtb致敏者的年龄大于未感染Mtb者(中位数[IQR],54 [39-64] vs 47 [33-62]岁)。与未感染者相比,Mtb致敏与T2DM(调整后绝对风险差异,9.34% [95% CI, 2.38%-15.0%]; P < .001)和胰岛素抵抗增加(调整后中位差异,0.16 [95% CI, .03-.29]; P = .014)相关,但与β细胞功能障碍无关(调整后中位差异,-3.1 [95% CI, -10.4 to 4.3]; P = .42)。在中介分析中,胰岛素抵抗介导了Mtb致敏与T2DM关系总效应的18.3% (95% CI, 3.29%-36.0%; P = .020):结论:有必要对结核病后发生的 T2DM 进行明确的前瞻性研究。尽管如此,我们的研究结果表明,暴露于Mtb可能是T2DM的一个新的风险因素,其驱动因素可能是胰岛素抵抗的增加。
{"title":"Association Between <i>Mycobacterium tuberculosis</i> Sensitization and Insulin Resistance Among US Adults Screened for Type 2 Diabetes Mellitus.","authors":"Itai M Magodoro, Aloice Aluoch, Brian Claggett, Moffat J Nyirenda, Mark J Siedner, Katalina A Wilkinson, Robert J Wilkinson, Ntobeko A B Ntusi","doi":"10.1093/ofid/ofae568","DOIUrl":"10.1093/ofid/ofae568","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) may be a long-term sequela of infection with <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) by mechanisms that remain to be fully explained. We evaluated the association between <i>Mtb</i> sensitization and T2DM and, via mediation analysis, the extent to which it is mediated by insulin resistance and/or β-cell failure.</p><p><strong>Methods: </strong>Adults were assessed for T2DM by fasting plasma glucose, 2-hour oral glucose tolerance testing, and hemoglobin A<sub>1c</sub>; β-cell dysfunction and insulin resistance by homoeostasis model assessment 2; and <i>Mtb</i> sensitization by tuberculin skin testing. Associations between <i>Mtb</i> sensitization and T2DM were modeled with probit regression and decomposed into indirect effects of β-cell dysfunction and insulin resistance. Analyses were adjusted for sociodemographic, behavioral, and clinical characteristics.</p><p><strong>Results: </strong>We included 1843 adults. Individuals with <i>Mtb</i> sensitization were older than those without <i>Mtb</i> (median [IQR], 54 [39-64] vs 47 [33-62] years). As compared with being uninfected, <i>Mtb</i> sensitization was associated with T2DM (adjusted absolute risk difference, 9.34% [95% CI, 2.38%-15.0%]; <i>P</i> < .001) and increased insulin resistance (adjusted median difference, 0.16 [95% CI, .03-.29]; <i>P</i> = .014) but not β-cell dysfunction (adjusted median difference, -3.1 [95% CI, -10.4 to 4.3]; <i>P</i> = .42). In mediation analyses, insulin resistance mediated 18.3% (95% CI, 3.29%-36.0%; <i>P</i> = .020) of the total effect of the association between <i>Mtb</i> sensitization and T2DM.</p><p><strong>Conclusions: </strong>Definitive prospective studies examining incident T2DM following tuberculosis are warranted. Notwithstanding, our findings suggest that exposure to <i>Mtb</i> may be a novel risk factor for T2DM, likely driven by an increase in insulin resistance.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 10","pages":"ofae568"},"PeriodicalIF":3.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Let's Have a Chat: How Well Does an Artificial Intelligence Chatbot Answer Clinical Infectious Diseases Pharmacotherapy Questions? 我们来聊聊人工智能聊天机器人如何回答临床传染病药物治疗问题?
IF 3.8 4区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-25 eCollection Date: 2024-11-01 DOI: 10.1093/ofid/ofae641
Wesley D Kufel, Kathleen D Hanrahan, Robert W Seabury, Katie A Parsels, Jason C Gallagher, Conan MacDougall, Elizabeth W Covington, Elias B Chahine, Rachel S Britt, Jeffrey M Steele

Background: It is unknown whether ChatGPT provides quality responses to infectious diseases (ID) pharmacotherapy questions. This study surveyed ID pharmacist subject matter experts (SMEs) to assess the quality of ChatGPT version 3.5 (GPT-3.5) responses.

Methods: The primary outcome was the percentage of GPT-3.5 responses considered useful by SME rating. Secondary outcomes were SMEs' ratings of correctness, completeness, and safety. Rating definitions were based on literature review. One hundred ID pharmacotherapy questions were entered into GPT-3.5 without custom instructions or additional prompts, and responses were recorded. A 0-10 rating scale for correctness, completeness, and safety was developed and validated for interrater reliability. Continuous and categorical variables were assessed for interrater reliability via average measures intraclass correlation coefficient and Fleiss multirater kappa, respectively. SMEs' responses were compared by the Kruskal-Wallis test and chi-square test for continuous and categorical variables.

Results: SMEs considered 41.8% of responses useful. Median (IQR) ratings for correctness, completeness, and safety were 7 (4-9), 5 (3-8), and 8 (4-10), respectively. The Fleiss multirater kappa for usefulness was 0.379 (95% CI, .317-.441) indicating fair agreement, and intraclass correlation coefficients were 0.820 (95% CI, .758-.870), 0.745 (95% CI, .656-.816), and 0.833 (95% CI, .775-.880) for correctness, completeness, and safety, indicating at least substantial agreement. No significant difference was observed among SME responses for percentage of responses considered useful.

Conclusions: Fewer than 50% of GPT-3.5 responses were considered useful by SMEs. Responses were mostly considered correct and safe but were often incomplete, suggesting that GPT-3.5 responses may not replace an ID pharmacist's responses.

背景:目前尚不清楚 ChatGPT 是否能高质量地回答传染病(ID)药物治疗问题。本研究对 ID 药剂师主题专家(SMEs)进行了调查,以评估 ChatGPT 3.5 版(GPT-3.5)回复的质量:主要结果是 SME 评级认为有用的 GPT-3.5 回答的百分比。次要结果是中小企业对正确性、完整性和安全性的评分。评分定义基于文献综述。在 GPT-3.5 中输入了 100 个 ID 药物治疗问题,没有自定义说明或额外提示,并记录了回复。针对正确性、完整性和安全性制定了 0-10 级评分表,并对评分者之间的可靠性进行了验证。连续变量和分类变量分别通过平均测量类内相关系数和弗莱斯多变量卡帕评估研究者之间的可靠性。通过 Kruskal-Wallis 检验和卡方检验对中小型企业的连续变量和分类变量进行比较:中小型企业认为 41.8%的答复有用。正确性、完整性和安全性的评分中位数(IQR)分别为 7(4-9)、5(3-8)和 8(4-10)。有用性的弗莱克斯多方卡帕值为 0.379(95% CI,.317-.441),表明一致性尚可;正确性、完整性和安全性的类内相关系数分别为 0.820(95% CI,.758-.870)、0.745(95% CI,.656-.816)和 0.833(95% CI,.775-.880),表明至少基本一致。在被认为有用的回答百分比方面,中小企业的回答没有明显差异:结论:中小型企业认为有用的 GPT-3.5 答复不到 50%。大多数答复被认为是正确和安全的,但往往不完整,这表明 GPT-3.5 答复可能无法取代 ID 药剂师的答复。
{"title":"Let's Have a Chat: How Well Does an Artificial Intelligence Chatbot Answer Clinical Infectious Diseases Pharmacotherapy Questions?","authors":"Wesley D Kufel, Kathleen D Hanrahan, Robert W Seabury, Katie A Parsels, Jason C Gallagher, Conan MacDougall, Elizabeth W Covington, Elias B Chahine, Rachel S Britt, Jeffrey M Steele","doi":"10.1093/ofid/ofae641","DOIUrl":"https://doi.org/10.1093/ofid/ofae641","url":null,"abstract":"<p><strong>Background: </strong>It is unknown whether ChatGPT provides quality responses to infectious diseases (ID) pharmacotherapy questions. This study surveyed ID pharmacist subject matter experts (SMEs) to assess the quality of ChatGPT version 3.5 (GPT-3.5) responses.</p><p><strong>Methods: </strong>The primary outcome was the percentage of GPT-3.5 responses considered useful by SME rating. Secondary outcomes were SMEs' ratings of correctness, completeness, and safety. Rating definitions were based on literature review. One hundred ID pharmacotherapy questions were entered into GPT-3.5 without custom instructions or additional prompts, and responses were recorded. A 0-10 rating scale for correctness, completeness, and safety was developed and validated for interrater reliability. Continuous and categorical variables were assessed for interrater reliability via average measures intraclass correlation coefficient and Fleiss multirater kappa, respectively. SMEs' responses were compared by the Kruskal-Wallis test and chi-square test for continuous and categorical variables.</p><p><strong>Results: </strong>SMEs considered 41.8% of responses useful. Median (IQR) ratings for correctness, completeness, and safety were 7 (4-9), 5 (3-8), and 8 (4-10), respectively. The Fleiss multirater kappa for usefulness was 0.379 (95% CI, .317-.441) indicating fair agreement, and intraclass correlation coefficients were 0.820 (95% CI, .758-.870), 0.745 (95% CI, .656-.816), and 0.833 (95% CI, .775-.880) for correctness, completeness, and safety, indicating at least substantial agreement. No significant difference was observed among SME responses for percentage of responses considered useful.</p><p><strong>Conclusions: </strong>Fewer than 50% of GPT-3.5 responses were considered useful by SMEs. Responses were mostly considered correct and safe but were often incomplete, suggesting that GPT-3.5 responses may not replace an ID pharmacist's responses.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae641"},"PeriodicalIF":3.8,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Randomized Controlled Trial of the Immunogenicity and Safety of a Serum-Free Purified Vero Rabies Vaccine (PVRV-NG2) Using a Simulated Postexposure Zagreb Regimen With Human Rabies Immunoglobulin in Adults in Thailand. 无血清纯化狂犬病疫苗(PVRV-NG2)的免疫原性和安全性随机对照试验--在泰国成人中使用人狂犬病免疫球蛋白的模拟暴露后萨格勒布疗法》(Randomized Controlled Trial of Immunogenicity and Safety of a Serum-Free Purified Vero Rabies Vaccine (PVRV-NG2) Using a Simulated Postexposure Zagreb Regimen with Human Rabies Immunoglobulin in Adults in Thailand)。
IF 3.8 4区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-25 eCollection Date: 2024-11-01 DOI: 10.1093/ofid/ofae633
Danaya Chansinghakul, Terapong Tantawichien, Kriengsak Limkittikul, Winai Ratanasuwan, Yuancheng Wang, Celine Petit, Francoise Guinet-Morlot, Carina Frago, Andrea-Clemencia Pineda-Peña

Background: A serum-free, highly purified Vero rabies vaccine-next generation (PVRV-NG2) is under development. We conducted a phase III trial to describe the safety and immunogenicity profile of PVRV-NG2 compared with those of licensed purified Vero rabies vaccine (PVRV) in a simulated rabies postexposure prophylaxis (PEP) Zagreb regimen in Thailand.

Methods: Healthy adults aged ≥18 years (n = 201) were randomized in a 2:1 ratio to receive PVRV-NG2 or PVRV in a rabies PEP Zagreb (days 0, 7, 21 [2-1-1]) regimen, with concomitant human rabies immunoglobulin (HRIG) at day 0. Immunogenicity end points included the proportion of participants with rabies virus-neutralizing antibody (RVNA) titers ≥0.5 IU/mL at days 0, 14, and 35. Safety outcomes were also assessed.

Results: A total of 199 participants completed the study (PVRV-NG2 n = 133, PVRV n = 66). In the PVRV-NG2 group and PVRV group, respectively, 91.0% (95% CI, 84.1%-95.6%) and 94.6% (95% CI, 85.1%-98.9%) had RVNA titers ≥0.5 IU/mL at day 14, increasing to 100% (95% CI, 96.8%-100%) and 100% (95% CI, 93.5%-100%) by day 35. The vaccines had similar safety profiles, and there were no safety concerns.

Conclusions: PVRV-NG2 showed acceptable safety and immunogenicity profiles when co-administered with HRIG in a simulated PEP Zagreb regimen in healthy adults in Thailand.

背景:一种无血清、高度纯化的下一代 Vero 狂犬病疫苗(PVRV-NG2)正在开发中。我们在泰国进行了一项 III 期试验,在模拟狂犬病暴露后预防 (PEP) 的萨格勒布方案中,比较 PVRV-NG2 与已获许可的纯化 Vero 狂犬病疫苗 (PVRV) 的安全性和免疫原性。方法:年龄≥18 岁的健康成人(n = 201)按 2:1 的比例随机接受 PVRV-NG2 或 PVRV 的狂犬病 PEP 萨格勒布方案(第 0、7、21 [2-1-1]天),第 0 天同时注射人狂犬病免疫球蛋白 (HRIG)。此外还评估了安全性结果:共有 199 名参与者完成了研究(PVRV-NG2 n = 133,PVRV n = 66)。在PVRV-NG2组和PVRV组中,第14天RVNA滴度≥0.5 IU/mL的分别为91.0%(95% CI,84.1%-95.6%)和94.6%(95% CI,85.1%-98.9%),第35天增至100%(95% CI,96.8%-100%)和100%(95% CI,93.5%-100%)。两种疫苗的安全性相似,没有安全性问题:结论:PVRV-NG2 与 HRIG 共同用于泰国健康成人的模拟 PEP Zagreb 方案时,显示出了可接受的安全性和免疫原性。
{"title":"Randomized Controlled Trial of the Immunogenicity and Safety of a Serum-Free Purified Vero Rabies Vaccine (PVRV-NG2) Using a Simulated Postexposure Zagreb Regimen With Human Rabies Immunoglobulin in Adults in Thailand.","authors":"Danaya Chansinghakul, Terapong Tantawichien, Kriengsak Limkittikul, Winai Ratanasuwan, Yuancheng Wang, Celine Petit, Francoise Guinet-Morlot, Carina Frago, Andrea-Clemencia Pineda-Peña","doi":"10.1093/ofid/ofae633","DOIUrl":"10.1093/ofid/ofae633","url":null,"abstract":"<p><strong>Background: </strong>A serum-free, highly purified Vero rabies vaccine-next generation (PVRV-NG2) is under development. We conducted a phase III trial to describe the safety and immunogenicity profile of PVRV-NG2 compared with those of licensed purified Vero rabies vaccine (PVRV) in a simulated rabies postexposure prophylaxis (PEP) Zagreb regimen in Thailand.</p><p><strong>Methods: </strong>Healthy adults aged ≥18 years (n = 201) were randomized in a 2:1 ratio to receive PVRV-NG2 or PVRV in a rabies PEP Zagreb (days 0, 7, 21 [2-1-1]) regimen, with concomitant human rabies immunoglobulin (HRIG) at day 0. Immunogenicity end points included the proportion of participants with rabies virus-neutralizing antibody (RVNA) titers ≥0.5 IU/mL at days 0, 14, and 35. Safety outcomes were also assessed.</p><p><strong>Results: </strong>A total of 199 participants completed the study (PVRV-NG2 n = 133, PVRV n = 66). In the PVRV-NG2 group and PVRV group, respectively, 91.0% (95% CI, 84.1%-95.6%) and 94.6% (95% CI, 85.1%-98.9%) had RVNA titers ≥0.5 IU/mL at day 14, increasing to 100% (95% CI, 96.8%-100%) and 100% (95% CI, 93.5%-100%) by day 35. The vaccines had similar safety profiles, and there were no safety concerns.</p><p><strong>Conclusions: </strong>PVRV-NG2 showed acceptable safety and immunogenicity profiles when co-administered with HRIG in a simulated PEP Zagreb regimen in healthy adults in Thailand.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae633"},"PeriodicalIF":3.8,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated With Death at 30 Days and Evaluation of Clinical Risk Scores Among Patients With Cancer Admitted With Postchemotherapy Infection in Uganda: A Prospective Cohort Study. 乌干达因化疗后感染入院的癌症患者 30 天内死亡的相关因素及临床风险评分评估:前瞻性队列研究
IF 3.8 4区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-25 eCollection Date: 2024-11-01 DOI: 10.1093/ofid/ofae634
Ambaru Jacinta Ojia, Sophie E Lyon, Jane Francis Birungi, Catherine Owomugisha, Rose Muhindo, Semei Buwambaza Sekitene, Christopher C Moore, Edwin Nuwagira

Background: Little is known about outcomes from cancer chemotherapy--associated infections in sub-Saharan Africa. Accordingly, among patients with cancer admitted with postchemotherapy infection in Mbarara, Uganda, we aimed to determine (1) the 30-day case fatality rate, (2) factors associated with mortality rate, and (3) clinical risk score performance.

Methods: We enrolled participants aged ≥18 years if they (1) received cancer chemotherapy within the past 30 days, (2) were admitted to the oncology ward, and (3) were prescribed intravenous antibiotics. We used Cox proportional hazards regression to determine predictors of death at 30 days and calculated the area under the receiver operating characteristic curve (AUC) for each clinical risk score.

Results: Among 150 participants, 67 (45%) were female, and the median (interquartile range) age was 56 (43-66) years. Esophageal cancer (18%) and pneumonia (42%) were the most common cancer and infection, respectively. Death occurred within 30 days in 63 participants (42%). Quick Sequential Organ Failure Assessment (qSOFA) score ≥2 (adjusted hazard ratio, 2.51 [95% confidence interval, 1.42-4.44]; P = .001), and Universal Vital Assessment (UVA) score >4 (2.13 [.08-4.18, P = .03) were independently associated with death at 30 days. An Eastern Cooperative Oncology Group (ECOG) score ≥3 was similarly independently associated with death at 30 days in the qSOFA and UVA models. The AUCs for qSOFA and UVA scores were 0.70 (95% confidence interval, .63-.79) and 0.72 (.64-.80), respectively.

Conclusions: In participants with postchemotherapy infection in Mbarara, Uganda, the case fatality rate was high. ECOG, qSOFA, and UVA scores were associated with death at 30 days.

背景:撒哈拉以南非洲地区对癌症化疗相关感染的结果知之甚少。因此,在乌干达姆巴拉拉因化疗后感染入院的癌症患者中,我们旨在确定(1)30 天内的病死率;(2)与病死率相关的因素;以及(3)临床风险评分表现:我们招募了年龄≥18 岁的参与者,条件是:(1) 在过去 30 天内接受过癌症化疗;(2) 住过肿瘤病房;(3) 被处方静脉注射抗生素。我们使用 Cox 比例危险度回归来确定 30 天后的死亡预测因素,并计算每个临床风险评分的接收器操作特征曲线下面积(AUC):在150名参与者中,67人(45%)为女性,年龄中位数(四分位数间距)为56(43-66)岁。食道癌(18%)和肺炎(42%)分别是最常见的癌症和感染。63名参与者(42%)在30天内死亡。快速器官功能衰竭评估(qSOFA)评分≥2(调整后危险比为2.51[95%置信区间为1.42-4.44];P = .001)和通用生命评估(UVA)评分>4(2.13[.08-4.18, P = .03)与30天内的死亡独立相关。在 qSOFA 和 UVA 模型中,东部肿瘤合作组 (ECOG) 评分≥3 同样与 30 天后的死亡独立相关。qSOFA和UVA评分的AUC分别为0.70(95%置信区间,.63-.79)和0.72(.64-.80):结论:在乌干达姆巴拉拉接受化疗后感染的患者中,病死率很高。ECOG、qSOFA和UVA评分与30天后的死亡有关。
{"title":"Factors Associated With Death at 30 Days and Evaluation of Clinical Risk Scores Among Patients With Cancer Admitted With Postchemotherapy Infection in Uganda: A Prospective Cohort Study.","authors":"Ambaru Jacinta Ojia, Sophie E Lyon, Jane Francis Birungi, Catherine Owomugisha, Rose Muhindo, Semei Buwambaza Sekitene, Christopher C Moore, Edwin Nuwagira","doi":"10.1093/ofid/ofae634","DOIUrl":"10.1093/ofid/ofae634","url":null,"abstract":"<p><strong>Background: </strong>Little is known about outcomes from cancer chemotherapy--associated infections in sub-Saharan Africa. Accordingly, among patients with cancer admitted with postchemotherapy infection in Mbarara, Uganda, we aimed to determine (1) the 30-day case fatality rate, (2) factors associated with mortality rate, and (3) clinical risk score performance.</p><p><strong>Methods: </strong>We enrolled participants aged ≥18 years if they (1) received cancer chemotherapy within the past 30 days, (2) were admitted to the oncology ward, and (3) were prescribed intravenous antibiotics. We used Cox proportional hazards regression to determine predictors of death at 30 days and calculated the area under the receiver operating characteristic curve (AUC) for each clinical risk score.</p><p><strong>Results: </strong>Among 150 participants, 67 (45%) were female, and the median (interquartile range) age was 56 (43-66) years. Esophageal cancer (18%) and pneumonia (42%) were the most common cancer and infection, respectively. Death occurred within 30 days in 63 participants (42%). Quick Sequential Organ Failure Assessment (qSOFA) score ≥2 (adjusted hazard ratio, 2.51 [95% confidence interval, 1.42-4.44]; <i>P</i> = .001), and Universal Vital Assessment (UVA) score >4 (2.13 [.08-4.18, <i>P</i> = .03) were independently associated with death at 30 days. An Eastern Cooperative Oncology Group (ECOG) score ≥3 was similarly independently associated with death at 30 days in the qSOFA and UVA models. The AUCs for qSOFA and UVA scores were 0.70 (95% confidence interval, .63-.79) and 0.72 (.64-.80), respectively.</p><p><strong>Conclusions: </strong>In participants with postchemotherapy infection in Mbarara, Uganda, the case fatality rate was high. ECOG, qSOFA, and UVA scores were associated with death at 30 days.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae634"},"PeriodicalIF":3.8,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatitis B Triple Panel Testing Implementation in the Obstetric Care Setting: Unique Predictors of Hepatitis B Virus Vaccine Immunity, Exposure, and Positivity. 在产科护理环境中实施乙肝三项检测:乙型肝炎病毒疫苗免疫、暴露和阳性的独特预测因素。
IF 3.8 4区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-23 eCollection Date: 2024-11-01 DOI: 10.1093/ofid/ofae632
Natalia Schmidt, Jeanette Rios, Lauren Alpert, Anna Mageras, Whitney Lieb, Tatyana Kushner
{"title":"Hepatitis B Triple Panel Testing Implementation in the Obstetric Care Setting: Unique Predictors of Hepatitis B Virus Vaccine Immunity, Exposure, and Positivity.","authors":"Natalia Schmidt, Jeanette Rios, Lauren Alpert, Anna Mageras, Whitney Lieb, Tatyana Kushner","doi":"10.1093/ofid/ofae632","DOIUrl":"10.1093/ofid/ofae632","url":null,"abstract":"","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae632"},"PeriodicalIF":3.8,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond Words: Enhancing Clinical Guideline Comprehension With Icons. 超越文字:用图标加强临床指南的理解。
IF 3.8 4区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-23 eCollection Date: 2024-11-01 DOI: 10.1093/ofid/ofae637
Isin Y Comba, John C O'Horo, Joel E Gordon, Yngve Falck-Ytter, Matthew M Moore, Rebecca L Morgan, Reem A Mustafa, Adarsh Bhimraj

Background: The Grading Recommendations, Assessment, Development, and Evaluations (GRADE) framework is widely applied in clinical guidelines to facilitate transparent evidence evaluation. While developing Infectious Diseases Society of America (IDSA) guidelines on the management of patients with coronavirus disease 2019 (COVID-19), panel members suggested developing and implementing a visual aid to enable quicker identification of key information by providers at bedside seeking guidance.

Methods: We conducted a mixed-methods study evaluating the usability of a newly designed infographic/icon using a survey and focus groups. The survey incorporated a simulated COVID-19 IDSA guideline with and without the icon, followed by comprehension questions. Focus group discussions provided qualitative feedback on the GRADE methodology and icon usability.

Results: The survey was returned by 289 health care providers. There was no statistical difference in the correct response rates between icon-aided and non-icon-aided guideline questions (McNemar's chi-square test, P > .1 for both questions). Interactions with the icon notably increased the time taken and number of clicks required to respond to the first question (Wilcoxon signed-rank test, P < .01). In contrast, response time did not differ between versions for the second question (P = .38). Most subjects (85%) indicated that the icon improved the readability of the guidelines. A focus group follow-up suggested alternative designs for the icon.

Conclusions: This study highlights the promise of iconography in clinical guidelines, although the specific icons tested did not measurably improve usability metrics. Future research should focus on icon design and testing within a formal usability framework, considering the impact of GRADE language on user experience.

背景:建议、评估、发展和评价分级(GRADE)框架被广泛应用于临床指南,以促进透明的证据评估。在制定美国传染病学会(IDSA)2019年冠状病毒疾病患者管理指南(COVID-19)时,专家组成员建议开发并实施一种可视化辅助工具,以便在床边寻求指导的医护人员能够更快地识别关键信息:我们开展了一项混合方法研究,通过调查和焦点小组对新设计的信息图/图标的可用性进行评估。调查包括有图标和无图标的模拟 COVID-19 IDSA 指南,然后是理解问题。焦点小组讨论提供了有关 GRADE 方法和图标可用性的定性反馈:共有 289 名医疗服务提供者返回了调查问卷。图标辅助和非图标辅助指南问题的正确回答率没有统计学差异(McNemar 的卡方检验,两个问题的 P > .1)。与图标的交互明显增加了回答第一个问题所需的时间和点击次数(Wilcoxon 符号秩检验,P < .01)。相比之下,不同版本对第二个问题的回答时间没有差异(P = .38)。大多数受试者(85%)表示,图标提高了指南的可读性。焦点小组的后续活动建议对图标进行其他设计:本研究强调了图标设计在临床指南中的应用前景,尽管测试的特定图标并未显著改善可用性指标。未来的研究应侧重于图标设计,并在正式的可用性框架内进行测试,同时考虑 GRADE 语言对用户体验的影响。
{"title":"Beyond Words: Enhancing Clinical Guideline Comprehension With Icons.","authors":"Isin Y Comba, John C O'Horo, Joel E Gordon, Yngve Falck-Ytter, Matthew M Moore, Rebecca L Morgan, Reem A Mustafa, Adarsh Bhimraj","doi":"10.1093/ofid/ofae637","DOIUrl":"https://doi.org/10.1093/ofid/ofae637","url":null,"abstract":"<p><strong>Background: </strong>The Grading Recommendations, Assessment, Development, and Evaluations (GRADE) framework is widely applied in clinical guidelines to facilitate transparent evidence evaluation. While developing Infectious Diseases Society of America (IDSA) guidelines on the management of patients with coronavirus disease 2019 (COVID-19), panel members suggested developing and implementing a visual aid to enable quicker identification of key information by providers at bedside seeking guidance.</p><p><strong>Methods: </strong>We conducted a mixed-methods study evaluating the usability of a newly designed infographic/icon using a survey and focus groups. The survey incorporated a simulated COVID-19 IDSA guideline with and without the icon, followed by comprehension questions. Focus group discussions provided qualitative feedback on the GRADE methodology and icon usability.</p><p><strong>Results: </strong>The survey was returned by 289 health care providers. There was no statistical difference in the correct response rates between icon-aided and non-icon-aided guideline questions (McNemar's chi-square test, <i>P</i> > .1 for both questions). Interactions with the icon notably increased the time taken and number of clicks required to respond to the first question (Wilcoxon signed-rank test, <i>P</i> < .01). In contrast, response time did not differ between versions for the second question (<i>P</i> = .38). Most subjects (85%) indicated that the icon improved the readability of the guidelines. A focus group follow-up suggested alternative designs for the icon.</p><p><strong>Conclusions: </strong>This study highlights the promise of iconography in clinical guidelines, although the specific icons tested did not measurably improve usability metrics. Future research should focus on icon design and testing within a formal usability framework, considering the impact of GRADE language on user experience.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae637"},"PeriodicalIF":3.8,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Open Forum Infectious Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1